Abstract. Oligonucleotides and their analogs can form specific complexes with RNA, DNA and various proteins interacting with nucleic acids. Results of in vitro studies evidence that the compounds may affect expression of specific genes and can be considered as potential efficient and specific biologically active compounds of therapeutic value. Studies on antiviral activity of oligonucleotides are strongly suggestive that they can suppress transcription and translation of viral nucleic acids and may interfere with the process of the virus -cell interaction. In this paper results of recent studies on oligonucleotide derivatives as gene-targeted drugs are surveyed.
INTRODUCTION
Fragments of nucleic acids, oligonucleotides, possess a unique capability of specific interactions with the most important biopolymers responsible for storage, processing and realization of genetic informationnucleic acids and proteins interacting with nucleic acids. Due to their unique targeting potential, oligonucleotides and oligonucleotide analogs are considered as promising structures for design of novel biologically active compounds that will be able to inactivate foreign genetic information of infectious agents and regulate expression of the inappropriately hnctioning cellular genes, e.g. overexpressing genes causing cancer. An important advantage of oligonucleotide derivatives is that in contrast to conventional drugs they affect directly genetic programs of organisms. The number of mRNA molecules is far less then the number of the protein molecules synthesized on the messengers and DNA is present at only a few copies per cell in the case of endogeneous genes or latent viruses. Therefore, in theory, only small amount of oligonucleotides is required to affect a given biochemical process. In contrast to the protein targeted drugs which can cause only temporal biochemical effects by inactivating specific proteins which will be produced again by the cell, the nucleic acid targeted oligonucleotides will inactivate or destroy the corresponding genetic material and stop competely production of the disease making protein. Therefore oligonucleotides offer the prospect of long acting therapeutics.
Since first attempts to develop reactive derivatives of oligonucleotides capable of modifying nucleic acids in sequence specific way (ref. l), and to use oligonucleotides to control viruses proliferation (ref. 2), considerable progress in design and biological studies of oligonucleotide analogs and conjugates has been achieves (for reviews see refs. 3-1 0) . Recent experimental studies demonstrate that chemical modifications of the natural oligonucleotides and synthetic analogs can improve pharmacological properties of the compounds and lead to the development of efficient therapeutics.
OLIGONUCLEOTIDES AS TARGETING STRUCTURES
A major advantage of oligonucleotides as targeting structures is the relatively simple rational design of the compounds capable of binding only to specific target nucleic acids. The principles of interaction of oligonucleotides with polynucleotides are well understood. Oligonucleotides can be directed in a WatsonCrick fascion toward complementary single-stranded nucleic acids or via triple-helix formation toward double-stranded DNA targets. Calculations show that oligonucleotides need to be only 15-1 8 nucleotides in
